SAN DIEGO --(BUSINESS WIRE)--Mar. 24, 2023-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces enrollment of the first patient in the FORESEE clinical trial with the Company’s proprietary cerebrospinal fluid assay CNSide (NCT05414123).
SAN DIEGO --(BUSINESS WIRE)--Mar. 1, 2023-- Biocept, Inc . (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, today announced that it has granted inducement stock options to purchase an aggregate of 7,360 shares of its common stock to two new employees.
SAN DIEGO --(BUSINESS WIRE)--Jan. 6, 2023-- Biocept, Inc. (NasdaqCM: BIOC ) today announced that it has commenced a process to explore and evaluate strategic alternatives to enhance shareholder value. Biocept has engaged EF Hutton, division of Benchmark Investments, Inc.
CNSide™ study data featured in three poster presentations at leading neuro-oncology annual meeting Participates in UCSF investigator-initiated study to better understand the development and progression of metastatic breast cancer to the central nervous system CNSide orders increased 8% over 2Q 2022
SAN DIEGO --(BUSINESS WIRE)--Nov. 18, 2022-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces the appointment of Quyen Dao-Haddock to its Board of Directors, effective immediately, increasing Board membership to eight. Ms.
Conducted by leading breast oncologists from UCSF under a grant from the California Breast Cancer Research Program and the University of California , San Francisco Brain Spore, the study will analyze results from cerebrospinal fluid using Biocept’s CNSide™ assay with results from blood samples SAN
Included first revenue from biopharma collaborator using CNSide™ in their therapeutics clinical trial First site opened for patient enrollment in the FORESEE trial to generate evidence of CNSide’s clinical utility Expanded the commercial availability of CNSide to metastatic melanoma CNSide™ orders
SAN DIEGO --(BUSINESS WIRE)--Oct. 19, 2022-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that management will present at the LD Micro Main Event XV on Wednesday, October 26 at 2:30 p.m. Pacific time ( 5:30 p.m. Eastern time ).
The cerebrospinal fluid (CSF) assay is now validated for melanomas and carcinomas, providing information to help physicians improve treatment decisions for more patients with advanced cancers SAN DIEGO --(BUSINESS WIRE)--Oct. 17, 2022-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular
Real-world case studies to be presented by leading neuro-oncologists Dr. Priya U. Kumthekar of Northwestern University and Dr. Seema A. Nagpal of Stanford University SAN DIEGO --(BUSINESS WIRE)--Oct. 14, 2022-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays,
